2013 Annual Meeting | Prognostication in the Era of Hypothermia

Date Wednesday 03/20/13

Time 06:30 AM - 08:30 AM Add To Calendar

Session Format This program will be presented both in-person and online

On Demand This program is not expected to be available in the meeting's On Demand product.

Event Type Seminar

Director(s) Romergryko G. Geocadin, MD, FAAN

Topic(s) Cerebrovascular Disease and Interventional Neurology

Learning Objectives Participants should learn recent advances in the use of therapeutic hypothermia for acute brain injuries, especially after resuscitation from cardiac arrest; how therapeutic hypothermia can alter the neurologic recovery; how therapeutic hypothermia may affect the previously established prognostic paradigms; and emerging prognostication modalities and its application in patients treated with hypothermia. Participants should also be familiar with the potential impact of therapeutic hypothermia in the determination of death by neurologic criteria; and be made aware of ongoing research, limitations of recent studies, and existing consensus statements and practice guidelines related to prognostication and therapeutic hypothermia from recognized professional organizations.

CME Available No CME available

Core Competencies Patient Care & Procedural Skills, Interpersonal and Communication Skills, Professionalism, Medical Knowledge, Practice-based Learning and Improvement, Systems-based Practice

Recommended Audience Trainee, General Neurologist, Specialist Neurologist, Non-neurologist

Teaching Styles Case-based, Didactic, Audience Participation

Event Timeline
06:30 AM - 07:00 AM		Therapeutic Hypothermia and Acute Brain Injury Romergryko G. Geocadin, MD, FAAN
07:00 AM - 07:30 AM		Prognostic Considerations with Therapeutic Hypothermia: Established Neurologic Paradigms Romergryko G. Geocadin, MD, FAAN
07:30 AM - 08:00 AM		Prognostic Considerations with Therapeutic Hypothermia: Emerging Neurologic Tests David M. Greer, MD, FAAN
08:00 AM - 08:10 AM		Therapeutic Hypothermia and Determination of Death by Neurologic Criteria David M. Greer, MD, FAAN
08:10 AM - 08:20 AM		Therapeutic Hypothermia: Ongoing Research and Future Direction Romergryko G. Geocadin, MD, FAAN
08:20 AM - 08:30 AM		Questions and Answers

Faculty Disclosures
Romergryko G. Geocadin, MD, FAAN	Dr. Geocadin has received personal compensation in the range of $5,000-$9,999 for serving as an Expert Witness for Medicolegal Consulting.
David M. Greer, MD, FAAN	Dr. Greer has received personal compensation in the range of $10,000-$49,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Thieme, Inc. Dr. Greer has received personal compensation in the range of $5,000-$9,999 for serving as an Expert Witness for multiple. An immediate family member of Dr. Greer has or had stock in Vertex Pharmaceuticals. The institution of Dr. Greer has received research support from NINDS. Dr. Greer has received publishing royalties from a publication relating to health care. Dr. Greer has received publishing royalties from a publication relating to health care. Dr. Greer has received publishing royalties from a publication relating to health care. Dr. Greer has a non-compensated relationship as a Treasurer-Elect with American Neurological Association that is relevant to AAN interests or activities. Dr. Greer has a non-compensated relationship as a President with Neurocritical Care Society that is relevant to AAN interests or activities.

��ɫ��

��ɫ��